The potential of siRNA based drug delivery in respiratory disorders: recent advances and progress

Research output: Contribution to journalReview article

Abstract

Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti-inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through post-transcriptional downregulation of the target gene expression. siRNA is essential in gene regulation, so is more favorable over other gene therapies due to its small size, high specificity, potency and no or low immune response. In chronic respiratory diseases, local and targeted delivery of siRNA is achieved via inhalation. The effectual delivery can be attained by the generation of aerosols via inhalers and nebulizers which overcomes anatomical barriers, alveolar macrophage clearance and mucociliary clearance. In this review, we discuss the different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery. siRNA mediated pro-inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions and thus providing sustained drug delivery, reduced therapeutic dose, and improved patient compliance. This review will be of high relevance to the formulation, biological and translational scientists working in the area of respiratory diseases.
LanguageEnglish
Pages1-17
Number of pages17
JournalDrug Development Research
Early online date16 Jul 2019
DOIs
Publication statusE-pub ahead of print - 16 Jul 2019

Fingerprint

RNA Interference
Pharmaceutical Preparations
Nebulizers and Vaporizers
Chronic Disease
Mucociliary Clearance
Essential Genes
Alveolar Macrophages
Therapeutics
Patient Compliance
Aerosols
MicroRNAs
Genetic Therapy
Respiratory System
Inhalation
Lung Diseases
Anti-Inflammatory Agents
Down-Regulation
Gene Expression
Mortality
Genes

Keywords

  • nanocarriers
  • Lung
  • polymer
  • delivery systems
  • RNA interference
  • pulmonary
  • siRNA

Cite this

@article{a9c5d376b1a44ed0a7e1936e29816e00,
title = "The potential of siRNA based drug delivery in respiratory disorders: recent advances and progress",
abstract = "Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti-inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through post-transcriptional downregulation of the target gene expression. siRNA is essential in gene regulation, so is more favorable over other gene therapies due to its small size, high specificity, potency and no or low immune response. In chronic respiratory diseases, local and targeted delivery of siRNA is achieved via inhalation. The effectual delivery can be attained by the generation of aerosols via inhalers and nebulizers which overcomes anatomical barriers, alveolar macrophage clearance and mucociliary clearance. In this review, we discuss the different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery. siRNA mediated pro-inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions and thus providing sustained drug delivery, reduced therapeutic dose, and improved patient compliance. This review will be of high relevance to the formulation, biological and translational scientists working in the area of respiratory diseases.",
keywords = "nanocarriers, Lung, polymer, delivery systems, RNA interference, pulmonary, siRNA",
author = "Tambuwala, {Murtaza M}",
year = "2019",
month = "7",
day = "16",
doi = "10.1002/ddr.21571",
language = "English",
pages = "1--17",

}

The potential of siRNA based drug delivery in respiratory disorders: recent advances and progress. / Tambuwala, Murtaza M.

16.07.2019, p. 1-17.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The potential of siRNA based drug delivery in respiratory disorders: recent advances and progress

AU - Tambuwala, Murtaza M

PY - 2019/7/16

Y1 - 2019/7/16

N2 - Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti-inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through post-transcriptional downregulation of the target gene expression. siRNA is essential in gene regulation, so is more favorable over other gene therapies due to its small size, high specificity, potency and no or low immune response. In chronic respiratory diseases, local and targeted delivery of siRNA is achieved via inhalation. The effectual delivery can be attained by the generation of aerosols via inhalers and nebulizers which overcomes anatomical barriers, alveolar macrophage clearance and mucociliary clearance. In this review, we discuss the different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery. siRNA mediated pro-inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions and thus providing sustained drug delivery, reduced therapeutic dose, and improved patient compliance. This review will be of high relevance to the formulation, biological and translational scientists working in the area of respiratory diseases.

AB - Lung diseases are the leading cause of mortality worldwide. The currently available therapies are not sufficient, leading to the urgent need for new therapies with sustained anti-inflammatory effects. Small/short or silencing interfering RNA (siRNA) has potential therapeutic implications through post-transcriptional downregulation of the target gene expression. siRNA is essential in gene regulation, so is more favorable over other gene therapies due to its small size, high specificity, potency and no or low immune response. In chronic respiratory diseases, local and targeted delivery of siRNA is achieved via inhalation. The effectual delivery can be attained by the generation of aerosols via inhalers and nebulizers which overcomes anatomical barriers, alveolar macrophage clearance and mucociliary clearance. In this review, we discuss the different siRNA nanocarrier systems for chronic respiratory diseases, for safe and effective delivery. siRNA mediated pro-inflammatory gene or miRNA targeting approach can be a useful approach in combating chronic respiratory inflammatory conditions and thus providing sustained drug delivery, reduced therapeutic dose, and improved patient compliance. This review will be of high relevance to the formulation, biological and translational scientists working in the area of respiratory diseases.

KW - nanocarriers

KW - Lung

KW - polymer

KW - delivery systems

KW - RNA interference

KW - pulmonary

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=85069931304&partnerID=8YFLogxK

U2 - 10.1002/ddr.21571

DO - 10.1002/ddr.21571

M3 - Review article

SP - 1

EP - 17

ER -